ReavenGM. Role of insulin resistance in human disease. Diabetes, 1988; 37:1595–1607.
2.
KaplanNM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med, 1989; 149:1514–1520.
3.
MatsuzawaY. Pathophysiology and molecular mechanisms of visceral fat syndrome: The Japanese experience. Diabetes Metab Rev, 1997; 13:3–13.
4.
YamauchiT, KamonJ, WakiH, et al.The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001; 7:941–946.
5.
SharpePA, BlanckHM, WilliamsJE, et al.Use of complementary and alternative medicine for weight control in the United States. J Altern Complement Med, 2007; 13:217–222.
6.
AritaY, KiharaS, OuchiN, et al.Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 1999; 257:79–83.
7.
YamauchiT, KadowakiT. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab, 2013; 17:185–196.
8.
OhmuraT, UedaK, KiyoharaY, et al.Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: The Hisayama Study. Diabetologia, 1993; 36:1198–1203.
9.
OtaT, TakamuraT, HiraiN, et al.Preobesity in World Health Organization classification involves the metabolic syndrome in Japanese. Diabetes Care, 2002; 25:1252–1253.
10.
Maxwell-HudsonC. The Complete Book of Massage. London: Dorling Kindersley, 1988.
